Breaking Update: Here’s a clear explanation of the latest developments related to Breaking News:Stocks to watch on February 12: IRCON, Godrej Ind, LG Electronics, Patanjali Foods and more– What Just Happened and why it matters right now.

Image count1 / 9

Promoters of Netweb Technologies are expected to sell up to a 3% stake in the company via block deals, sources told CNBC-TV18. The offer size is ₹514.5 crore, with a floor price set at ₹3,027 per share, according to sources. This floor price is at a discount of up to 4% compared to the last close.

Image count2 / 9

Patanjali Foods | Baba Ramdev-helmed Patanjali Foods Ltd on Wednesday (February 11) reported a net profit of ₹364.2 crore for the third quarter, down 26% from ₹491.2 crore in the year-ago period. Revenue for the quarter rose 16.5% to ₹10,483 crore, compared with ₹8,997 crore in the corresponding period last year. Earnings before interest, taxes, depreciation and amortisation (EBITDA) declined 22.2% to ₹433.4 crore, from ₹557.4 crore in the same quarter last year. EBITDA margin shrank to 4.1%, down from 6.2% in the year-ago period.

Image count3 / 9

Kirloskar Oil Engines | Kirloskar reported a strong Q3 performance, with net profit rising 56.2% year-on-year to ₹111.4 crore compared with ₹71.3 crore in the same quarter last year. Revenue grew 29.2% YoY to ₹1,872.6 crore from ₹1,449.3 crore, supported by improved business momentum. EBITDA increased 31.3% to ₹331.5 crore versus ₹252.5 crore, while margins edged up slightly to 17.7% from 17.4% a year ago.

Image count4 / 9

IRCON | State-owned engineering and construction firm IRCON International Ltd on Wednesday (February 11) reported a net profit of ₹99.9 crore for the third quarter, up 15.97% from ₹86.1 crore in the year-ago period. Revenue for the quarter declined 18.9% year-on-year to ₹2,119 crore versus ₹2,612.8 crore in Q3FY25.

AstraZeneca Pharma share price, AstraZeneca Pharma stock, AstraZeneca Pharma shares, AstraZeneca Pharma, AstraZeneca Pharma cancer drug, AstraZeneca Pharma cancer treatment drug, AstraZeneca Pharma endometrial cancer treatment drug,

(Photo Credit : CNBC-TV18 Library )

Image count5 / 9

AstraZeneca Pharma | AstraZeneca Pharma reported a mixed Q3 performance, with net profit rising 5.9% year-on-year to ₹32.6 crore compared with ₹30.8 crore in the same quarter last year. Revenue surged 39% YoY to ₹611.5 crore from ₹440.2 crore. However, EBITDA declined 41.7% to ₹44.8 crore versus ₹76.9 crore, leading to a sharp contraction in margins to 7.3% from 17.5% a year ago.

orkla india ipo subscription status

Image count6 / 9

Orkla India | The company reported a 13.98% year-on-year decline in net profit for the third quarter ended December 31, 2025, at ₹56.6 crore, compared with ₹65.8 crore in the same period last year. Revenue from operations rose 3.4% to ₹636 crore from ₹615.2 crore a year earlier, driven by volume-led growth, the company said.

Image count7 / 9

Protean eGov | IT company Protean eGov Technologies Ltd on Wednesday reported a net profit of ₹22.5 crore for the third quarter, down 2.2% from ₹23 crore in the year-ago period. Revenue for the quarter rose 13.1% to ₹228.9 crore, compared with ₹202.3 crore in the corresponding period last year, driven by strong performance in tax services and new businesses. Central Recordkeeping Agency revenues remained unchanged.

Image count8 / 9

LG Electronics | The company reported a weaker Q3 performance, with net profit declining 61.6% year-on-year to ₹89.6 crore compared with ₹233.4 crore in the same quarter last year. Revenue fell 6.4% YoY to ₹4,114.3 crore from ₹4,395.5 crore. EBITDA also dropped 42.6% to ₹195.7 crore versus ₹340.7 crore, while margins narrowed to 4.8% from 7.8% a year ago.

Image count9 / 9

Godrej Industries | It reported its Q3 (October-December) results with consolidated net profit rising 8.7% year-on-year to ₹204.5 crore compared with ₹188.2 crore in the same quarter last year. Godrej Industries’ revenue grew 4.7% to ₹5,051 crore from ₹4,824 crore a year ago. However, EBITDA declined 8.8% to ₹544.1 crore against ₹597 crore a year earlier, leading to a lower operating margin of 10.8% versus 12.4% in the previous year.